IMPRiND partner Tiago Outeiro, Director of the Department of Experimental Neurodegeneration and his team at the University Medical Center Goettingen (UMG), Germany has just published a study in the journal Nature Neuroscience, from Nature publishing group, describing the identification of a novel molecular pathway that can constitute a therapeutic target for cognitive defects in Parkinson’s disease.
A new study with IMPRIND partner Heutink, published in Science, further supports the notion that modulating synuclein levels matters in PD.
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.
The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.